中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 11
Nov.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(11): 2310-2316

Prognostic differences between primary biliary cholangitis patients positive for different autoantibodies and related influencing factors

DOI: 10.12449/JCH251117
  • 1.

    Fenyang College of Shanxi Medical University，Fenyang，Shanxi 032200，China

  • 2.

    Department of Infectious Diseases，Fenyang Hospital of Shanxi Province，Fenyang，Shanxi 032200，China

  • 3.

    Department of Infectious Diseases，Tangdu Hospital，Air Force Medical University，Xi’an 710038，China

Research funding:

Scientific Research Project of Shanxi Provincial Health Commission (2023XG112)

More Information
  • Corresponding author: ZHANG Yaowu， zyw5680@126.com （ORCID： 0009-0008-1165-5922）
  • Received Date: 2025-04-27
  • Accepted Date: 2025-05-23
  • Published Date: 2025-11-25
    Abstract
  •   Objective  To investigate the prognostic differences between primary biliary cholangitis （PBC） patients positive for different autoantibodies and the risk factors for poor prognosis， and to facilitate early and effective intervention for PBC patients.  Methods  A total of 141 patients who were diagnosed with PBC for the first time in Fenyang Hospital of Shanxi Province from January 2018 to December 2023 were enrolled and divided into group A （80 patients positive for anti-mitochondrial antibody M2 ［AMA-M2］ alone）， group B （36 patients positive for AMA-M2 and anti-gp210 antibody）， and group C （25 patients positive for AMA-M2 and anti-sp100 antibody）， and the three groups were compared in terms of general information， laboratory markers， and prognosis. The Globe score was used for prognostic evaluation， and a Globe score of<0.3 and the absence of liver cirrhosis at the time of confirmed diagnosis were defined as good prognosis， while a Globe score of ≥0.3 or the presence of liver cirrhosis at the time of confirmed diagnosis were defined as poor prognosis. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups， and the least significant difference t-test was used for further comparison between two groups； the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups， and the Dunn’s multiple test was used for further comparison between two groups； the chi-square test was used for comparison of categorical data between groups. The univariate and multivariate Logistic regression analyses were used to investigate the influencing factors for the prognosis of PBC patients； the receiver operating characteristic （ROC） curve was plotted， and the area under the ROC curve （AUC） was calculated.  Results  Compared with group A， groups B and C had a significantly higher proportion of male patients， a significantly higher detection rate of liver cirrhosis， significantly higher levels of ALT， TBil， and ALP， and significantly lower levels of PLT and Alb （all P<0.05）. The Globe score was calculated based on related indicators after treatment with ursodeoxycholic acid （UDCA） for 1 year， and the results showed that there was a significant difference in prognosis between the three groups （P<0.001）， and compared with group A， groups B and C had a significantly higher proportion of patients with a Globe score of ≥0.3 （P<0.05） and a significantly higher rate of suboptimal response to UDCA （P<0.05）. The univariate Logistic regression analysis showed that anti-gp210 antibody， anti-sp100 antibody， UDCA response， PLT， Alb， ALT， TBil， and ALP were associated with the prognosis of PBC patients （all P<0.05）. The variables meeting related conditions were included in the multivariate Logistic regression analysis， and the results showed that anti-gp210 antibody （odds ratio ［OR］=4.959， 95% confidence interval ［CI］： 1.112 — 22.122， P=0.036）， anti-sp100 antibody （OR=21.666， 95%CI： 1.542 — 304.449， P=0.023）， Alb （OR=0.899， 95%CI： 0.814 — 0.994， P=0.038）， PLT （OR=0.974， 95%CI： 0.963 — 0.985， P<0.001）， and UDCA response （OR=10.275， 95%CI： 1.047 — 100.831， P=0.046） were independent influencing factors for the prognosis of PBC patients. The ROC curve analysis showed that PLT had the best performance in predicting the prognosis of PBC patients， with an AUC of 0.824， a sensitivity of 85.7%， and a specificity of 71.7%.  Conclusion  Patients with dual positivity for AMA-M2 and anti-gp210 antibody， as well as those with dual positivity for AMA-M2 and anti-sp100 antibody， tend to have a poorer prognosis and a higher rate of suboptimal response to UDCA. Furthermore， positivity for anti-gp210 antibody， positivity for anti-sp100 antibody， thrombocytopenia， hypoalbuminemia， and suboptimal response to UDCA all indicate poor clinical prognosis.

     

    • FullText(HTML)
  • loading
    • References(27)
  • [1]
    SCHNABL B. PPAR agonists in primary biliary cholangitis[J]. N Engl J Med, 2024, 390( 9): 855- 858. DOI: 10.1056/nejme2313802.
    [2]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary biliary cholangitis(2021)[J]. J Clin Hepatol, 2022, 38( 1): 35- 41.

    中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38( 1): 35- 41.
    [3]
    HARMS MH, van BUUREN HR, CORPECHOT C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis[J]. J Hepatol, 2019, 71( 2): 357- 365. DOI: 10.1016/j.jhep.2019.04.001.
    [4]
    European Association for the Study of the Liver. EASL clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67( 1): 145- 172. DOI: 10.1016/j.jhep.2017.03.022.
    [5]
    YOU H, MA X, EFE C, et al. APASL clinical practice guidance: The diagnosis and management of patients with primary biliary cholangitis[J]. Hepatol Int, 2022, 16( 1): 1- 23. DOI: 10.1007/s12072-021-10276-6.
    [6]
    ZANDANELL S, STRASSER M, FELDMAN A, et al. Similar clinical outcome of AMA immunoblot-M2-negative compared to immunoblot-positive subjects over six years of follow-up[J]. Postgrad Med, 2021, 133( 3): 291- 298. DOI: 10.1080/00325481.2021.1885945.
    [7]
    HALDAR D, JANMOHAMED A, PLANT T, et al. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis[J]. Liver Int, 2021, 41( 3): 535- 544. DOI: 10.1111/liv.14688.
    [8]
    REIG A, NORMAN GL, GARCIA M, et al. Novel anti-hexokinase 1 antibodies are associated with poor prognosis in patients with primary biliary cholangitis[J]. Am J Gastroenterol, 2020, 115( 10): 1634- 1641. DOI: 10.14309/ajg.0000000000000690.
    [9]
    NAKAMURA M, KONDO H, MORI T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis[J]. Hepatology, 2007, 45( 1): 118- 127. DOI: 10.1002/hep.21472.
    [10]
    LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J]. Gastroenterology, 2015, 149( 7): 1804- 1812. DOI: 10.1053/j.gastro.2015.07.061.
    [11]
    YANG F, YANG Y, WANG Q, et al. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: The additional effect of anti-gp210[J]. Aliment Pharmacol Ther, 2017, 45( 5): 733- 743. DOI: 10.1111/apt.13927.
    [12]
    CHANG YH, WANG L, YUAN Z, et al. Application and evaluation of prognostic value of continuous scoring systems in different stages of primary biliary cholangitis patients in China[J]. Int J Dig Dis, 2019, 39( 2): 102- 110. DOI: 10.3969/j.issn.1673-534X.2019.02.008.

    常英昊, 王璐, 袁洲, 等. 连续预后评分系统在中国原发性胆汁性胆管炎不同分期患者中的应用及评价[J]. 国际消化病杂志, 2019, 39( 2): 102- 110. DOI: 10.3969/j.issn.1673-534X.2019.02.008.
    [13]
    LAMMERS WJ, van BUUREN HR, HIRSCHFIELD GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study[J]. Gastroenterology, 2014, 147( 6): 1338- 1349. DOI: 10.1053/j.gastro.2014.08.029.
    [14]
    HIRSCHFIELD GM, BEUERS U, KUPCINSKAS L, et al. A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA[J]. J Hepatol, 2021, 74( 2): 321- 329. DOI: 10.1016/j.jhep.2020.09.011.
    [15]
    NEVENS F, ANDREONE P, MAZZELLA G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375( 7): 631- 643. DOI: 10.1056/NEJMoa1509840.
    [16]
    TANAKA A, MA X, TAKAHASHI A, et al. Primary biliary cholangitis[J]. Lancet, 2024, 404( 10457): 1053- 1066. DOI: 10.1016/S0140-6736(24)01303-5.
    [17]
    HOURI I, HIRSCHFIELD GM. Primary biliary cholangitis: Pathophysiology[J]. Clin Liver Dis, 2024, 28( 1): 79- 92. DOI: 10.1016/j.cld.2023.06.006.
    [18]
    TANAKA A. Current understanding of primary biliary cholangitis[J]. Clin Mol Hepatol, 2021, 27( 1): 1- 21. DOI: 10.3350/cmh.2020.0028.
    [19]
    SAKUGAWA H, NAKASONE H, NAKAYOSHI T, et al. Epidemiology of primary biliary cirrhosis among women with elevated gamma-glutamyl transpeptidase levels in Okinawa, Japan[J]. Hepatol Res, 2003, 26( 4): 330- 336. DOI: 10.1016/s1386-6346(03)00167-0.
    [20]
    LIU ZC, WANG ZL, ZHENG JR, et al. Prevalence of primary biliary cholangitis in the Chinese general population and its influencing factors: A systematic review[J]. J Clin Hepatol, 2023, 39( 2): 325- 332. DOI: 10.3969/j.issn.1001-5256.2023.02.011.

    刘智成, 王资隆, 郑佳睿, 等. 我国一般人群原发性胆汁性胆管炎患病率及其影响因素的系统综述[J]. 临床肝胆病杂志, 2023, 39( 2): 325- 332. DOI: 10.3969/j.issn.1001-5256.2023.02.011.
    [21]
    HUANG CY, LIU YM, LIU H, et al. Study of clinical characteristics in patients with gp210 antibody-positive primary biliary cholangitis[J]. Chin J Hepatol, 2022, 30( 4): 419- 425. DOI: 10.3760/cma.j.cn501113-20210501-00216.

    黄春洋, 刘燕敏, 刘晖, 等. 抗gp210抗体阳性原发性胆汁性胆管炎患者临床特点研究[J]. 中华肝脏病杂志, 2022, 30( 4): 419- 425. DOI: 10.3760/cma.j.cn501113-20210501-00216.
    [22]
    WANG J, XIA J, YAN XM, et al. Plateletcrit as a potential index for predicting liver fibrosis in chronic hepatitis B[J]. J Viral Hepat, 2020, 27( 6): 602- 609. DOI: 10.1111/jvh.13264.
    [23]
    LIU YW, HAN K, LIU C, et al. Clinical characteristics and prognosis of concomitant primary biliary cholangitis and autoimmune diseases: A retrospective study[J]. Can J Gastroenterol Hepatol, 2021, 2021: 5557814. DOI: 10.1155/2021/5557814.
    [24]
    HU SL, ZHAO FR, HU Q, et al. Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis[J]. PLoS One, 2014, 9( 7): e101916. DOI: 10.1371/journal.pone.0101916.
    [25]
    LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2019, 69( 1): 394- 419. DOI: 10.1002/hep.30145.
    [26]
    MYTILINAIOU MG, MEYER W, SCHEPER T, et al. Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis[J]. Clin Chim Acta, 2012, 413( 15-16): 1211- 1216. DOI: 10.1016/j.cca.2012.03.020.
    [27]
    NAKAMURA M, TAKII Y, ITO M, et al. Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis[J]. J Autoimmun, 2006, 26( 2): 138- 145. DOI: 10.1016/j.jaut.2005.10.007.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (8) PDF downloads(5) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return